Literature DB >> 27323757

Downregulation of the long noncoding RNA TUG1 inhibits the proliferation, migration, invasion and promotes apoptosis of renal cell carcinoma.

Meng Zhang1,2, Wei Lu1,2, Yiqiang Huang3, Jizhou Shi4, Xun Wu2, Xiaolong Zhang2, Runze Jiang2, Zhiming Cai1, Song Wu5.   

Abstract

Long non-coding RNAs, a newly discovered category of noncoding genes, play a leading role in various biological processes, including tumorigenesis. In our study, we aimed to examine the TUG1 expression, and explore the influence of TUG1 silencing on cell proliferation and apoptosis in renal cell carcinoma (RCC) cell lines. The TUG1 expression level was detected using quantitative real-time PCR reverse transcription-polymerase chain reaction in 40 paired clear cell renal cell carcinoma (ccRCC) and adjacent paired normal tissues, as well as four RCC cell lines and one normal human proximal tubule epithelial cell line HK-2. Small interfering RNA was applied to suppress the TUG1 expression in RCC cell lines (A489 and A704). In vitro assays were conducted to further deliberate its potential functions in RCC progression. The relative TUG1 expression was significantly higher in ccRCC tissues compared to the adjacent normal renal tissues. In addition, higher TUG1 expression was equally detected in RCC cell lines (particularly in A498 and A704) compared to HK-2. The ccRCC specimens with higher TUG1 expression had a higher Fuhrman grade and larger tumor size than those with lower TUG1 expression. In vitro assays results suggested that knockdown of TUG1 suppressed RCC cells migration, invasion and proliferation, while the apoptosis process was activated. Our results indicate that TUG1 is identified as a novel oncogene in the morbid state of RCC, which potentially acts as a therapeutic target/biomarker in RCC. The graphic abstract of the present work.

Entities:  

Keywords:  Biomarker; Renal cell carcinoma; TUG1; siRNA–TUG1

Mesh:

Substances:

Year:  2016        PMID: 27323757     DOI: 10.1007/s10735-016-9683-2

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   2.611


  15 in total

1.  Upregulation of the long noncoding RNA TUG1 promotes proliferation and migration of esophageal squamous cell carcinoma.

Authors:  Youtao Xu; Jie Wang; Mantang Qiu; Lei Xu; Ming Li; Feng Jiang; Rong Yin; Lin Xu
Journal:  Tumour Biol       Date:  2014-10-31

2.  Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses.

Authors:  Moran N Cabili; Cole Trapnell; Loyal Goff; Magdalena Koziol; Barbara Tazon-Vega; Aviv Regev; John L Rinn
Journal:  Genes Dev       Date:  2011-09-02       Impact factor: 11.361

Review 3.  Renal-cell carcinoma.

Authors:  R J Motzer; N H Bander; D M Nanus
Journal:  N Engl J Med       Date:  1996-09-19       Impact factor: 91.245

4.  Analysis of long non-coding RNA expression profiles in gastric cancer.

Authors:  Wei-Jun Cao; Hai-Lu Wu; Bang-Shun He; Yu-Shu Zhang; Zhen-Yu Zhang
Journal:  World J Gastroenterol       Date:  2013-06-21       Impact factor: 5.742

5.  The noncoding RNA taurine upregulated gene 1 is required for differentiation of the murine retina.

Authors:  T L Young; T Matsuda; C L Cepko
Journal:  Curr Biol       Date:  2005-03-29       Impact factor: 10.834

6.  Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals.

Authors:  Mitchell Guttman; Ido Amit; Manuel Garber; Courtney French; Michael F Lin; David Feldser; Maite Huarte; Or Zuk; Bryce W Carey; John P Cassady; Moran N Cabili; Rudolf Jaenisch; Tarjei S Mikkelsen; Tyler Jacks; Nir Hacohen; Bradley E Bernstein; Manolis Kellis; Aviv Regev; John L Rinn; Eric S Lander
Journal:  Nature       Date:  2009-02-01       Impact factor: 49.962

7.  Long intergenic non-coding RNA TUG1 is overexpressed in urothelial carcinoma of the bladder.

Authors:  Yonghua Han; Yuchen Liu; Yaoting Gui; Zhiming Cai
Journal:  J Surg Oncol       Date:  2012-09-07       Impact factor: 3.454

8.  Upregulation of centromere protein H is associated with progression of renal cell carcinoma.

Authors:  Xun Wu; Youcheng Lin; Liping Shi; Yi Huang; Caiyong Lai; Yongqiang Wang; Meng Zhang; Shupeng Wang; Baoli Heng; Ganshen Yu; Xinghua Du; Lu Fang; Yu Fu; Jie Chen; Zexiong Guo; Zexuan Su; Song Wu
Journal:  J Mol Histol       Date:  2015-08-07       Impact factor: 2.611

9.  Prognostic prediction and diagnostic role of intercellular adhesion molecule-1 (ICAM1) expression in clear cell renal cell carcinoma.

Authors:  Xuebing Shi; Jifa Jiang; Xiaobing Ye; Yanyan Liu; Qiong Wu; Lu Wang
Journal:  J Mol Histol       Date:  2014-02-18       Impact factor: 2.611

10.  The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression.

Authors:  Thomas Derrien; Rory Johnson; Giovanni Bussotti; Andrea Tanzer; Sarah Djebali; Hagen Tilgner; Gregory Guernec; David Martin; Angelika Merkel; David G Knowles; Julien Lagarde; Lavanya Veeravalli; Xiaoan Ruan; Yijun Ruan; Timo Lassmann; Piero Carninci; James B Brown; Leonard Lipovich; Jose M Gonzalez; Mark Thomas; Carrie A Davis; Ramin Shiekhattar; Thomas R Gingeras; Tim J Hubbard; Cedric Notredame; Jennifer Harrow; Roderic Guigó
Journal:  Genome Res       Date:  2012-09       Impact factor: 9.043

View more
  28 in total

1.  LncRNA CCAT1 inhibits cell apoptosis of renal cell carcinoma through up-regulation of Livin protein.

Authors:  Shaoan Chen; Pengpeng Ma; Bin Li; Dawei Zhu; Xiude Chen; Yuzhu Xiang; Tengteng Wang; Xiangbin Ren; Chuan Liu; Xunbo Jin
Journal:  Mol Cell Biochem       Date:  2017-05-03       Impact factor: 3.396

2.  LncRNA TUG1 aggravates cardiomyocyte apoptosis and myocardial ischemia/reperfusion injury.

Authors:  Dongliang Fu; Tong Gao; Mengru Liu; Chunyan Li; Haiwei Li; Hong Jiang; Xianlun Fu
Journal:  Histol Histopathol       Date:  2021-10-20       Impact factor: 2.303

3.  Long non-coding RNA TUG1 promotes progression of oral squamous cell carcinoma through upregulating FMNL2 by sponging miR-219.

Authors:  Guangqi Yan; Xue Wang; Mingliang Yang; Li Lu; Qing Zhou
Journal:  Am J Cancer Res       Date:  2017-09-01       Impact factor: 6.166

4.  LncRNA CERNA2 is an independent predictor for clinical prognosis and is related to tumor development in gastric cancer.

Authors:  Jingjing Zhang; Xiao Han; Lei Jiang; Zhengquan Han; Zian Wang
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01

5.  Long non-coding RNA TUG1/microRNA-187-3p/TESC axis modulates progression of pituitary adenoma via regulating the NF-κB signaling pathway.

Authors:  Rui Zhang; Fan Yang; Haitao Fan; Haocong Wang; Qinghao Wang; Jianxin Yang; Tao Song
Journal:  Cell Death Dis       Date:  2021-05-21       Impact factor: 8.469

6.  TUG1, SPRY4-IT1, and HULC as valuable prognostic biomarkers of survival in cancer: A PRISMA-compliant meta-analysis.

Authors:  Yucheng Zhong; Zhicong Chen; Shuyuan Guo; Xinhui Liao; Haibiao Xie; Yien Zheng; Bin Cai; Peixian Huang; Yuhan Liu; Qun Zhou; Yuchen Liu; Weiren Huang
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.889

Review 7.  Long non-coding RNA implicated in the invasion and metastasis of head and neck cancer: possible function and mechanisms.

Authors:  Xiaobo Luo; Yan Qiu; Yuchen Jiang; Fangman Chen; Lu Jiang; Yu Zhou; Hongxia Dan; Xin Zeng; Yu L Lei; Qianming Chen
Journal:  Mol Cancer       Date:  2018-01-24       Impact factor: 27.401

Review 8.  Long non-coding RNAs as an epigenetic regulator in human cancers.

Authors:  Yutaka Kondo; Keiko Shinjo; Keisuke Katsushima
Journal:  Cancer Sci       Date:  2017-08-30       Impact factor: 6.716

9.  Downregulation of lncRNA TUG1 attenuates inflammation and apoptosis of renal tubular epithelial cell induced by ischemia-reperfusion by sponging miR-449b-5p via targeting HMGB1 and MMP2.

Authors:  Yuan Xu; Yulin Niu; Haiyang Li; Guanghui Pan
Journal:  Inflammation       Date:  2020-08       Impact factor: 4.657

10.  The prognostic potential and carcinogenesis of long non-coding RNA TUG1 in human cholangiocarcinoma.

Authors:  Yi Xu; Kaiming Leng; Zhenglong Li; Fumin Zhang; Xiangyu Zhong; Pengcheng Kang; Xingming Jiang; Yunfu Cui
Journal:  Oncotarget       Date:  2017-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.